A Prospective, observational real life study on the safety of the Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin regimen in patients with Compensated HCV Cirrhosis

Trial Profile

A Prospective, observational real life study on the safety of the Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin regimen in patients with Compensated HCV Cirrhosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver cirrhosis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 New trial record
    • 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top